PAHC — PHIBRO ANIMAL HEALTH CORP
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1069899 ·
Last close
$33.26
Market Cap
$700.74M
52W High
$60.08
52W Low
$32.30
ADV30
397,653
Next earnings
2026-05-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 383,543,000 | 125,675,000 | 44,653,000 | 24,024,000 | 1,445,118,000 | 54,929,000 | 1,083,291,000 |
| Dec 2025 | 373,910,000 | 132,656,000 | 50,326,000 | 27,459,000 | 1,405,553,000 | 55,486,000 | 1,073,192,000 |
| Sep 2025 | 363,893,000 | 119,783,000 | 51,260,000 | 26,527,000 | 1,385,524,000 | 72,769,000 | 1,073,843,000 |
| Jun 2025 | 378,697,000 | 110,009,000 | 33,718,000 | 17,224,000 | 1,360,900,000 | 68,039,000 | 1,075,218,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$93,080,000
Investing CF
$-63,483,000
Financing CF
$-42,634,000
CapEx
$-45,791,000
Dividends Paid
$-19,457,000
Buybacks
—
EPS Diluted TTM
$2.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$316,959,000
Inventory
$517,347,000
Receivables
$215,872,000
ST Investments
$19,022,000
EBIT TTM
$167,579,000
Pretax Income TTM
$126,227,000
Interest Exp TTM
$41,352,000
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,500,043,008
EBITDA
$234,754,000
Free Cash Flow
$-17,678,250
Enterprise Value
$2,059,723,392
Total Cash
$78,138,000
Total Debt
$788,678,976
Shares Out
21,068,682
Trailing EPS
$2.33
Book Value
$8.92
ROE
30.3%
ROA
8.4%
Div Yield
1.44%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 1,296,215,000 | 110,465,000 | 48,264,000 | 1,360,900,000 | 1,075,218,000 | — | 80,124,000 |
| Jun 2024 | 1,017,679,000 | 53,315,000 | 2,416,000 | 982,184,000 | 725,543,000 | — | 87,594,000 |
| Jun 2023 | 977,889,000 | 71,847,000 | 32,606,000 | 971,397,000 | 688,888,000 | — | 13,310,000 |
| Jun 2022 | 942,261,000 | 78,986,000 | 49,175,000 | 931,699,000 | 669,257,000 | — | 31,649,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.34
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $35.00 · spot: $33.79 · call volume: 101 · put volume: 53
Expected Move to 2026-09-18:
±$8.60
(25.45%) —
implied range
$25.19 –
$42.39
· ATM straddle on $35.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ANL | Adlai Nortye Ltd. | $700.12M | $11.92 | — |
| CYRX | Cryoport, Inc. | $705.63M | $14.00 | — |
| DSGN | Design Therapeutics, Inc. | $685.15M | $10.97 | — |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $684.92M | $8.55 | — |
| BIOA | BioAge Labs, Inc. | $738.36M | $16.61 | — |
News headlines (Yahoo Finance, 1h cache)
Should Value Investors Buy Phibro Animal Health (PAHC) Stock?
2026-05-25 13:40 · Yahoo
Phibro's CEO transition puts this insider sale in context
2026-05-23 21:27 · Yahoo
1 Russell 2000 Stock with Promising Prospects and 2 We Brush Off
2026-05-23 11:00 · Yahoo
3 of Wall Street’s Favorite Stocks Walking a Fine Line
2026-05-22 22:12 · Yahoo
Phibro Animal Health Corporation to Participate in Stifel Jaws & Paws Conference
2026-05-21 20:30 · Yahoo
GlobeFlex Exits NCR Atleos After Brink’s Buyout Deal
2026-05-20 21:54 · Yahoo
Phibro Animal Health Corporation (PAHC) Price Target Cut to $44 by Citi Amid Sector Pressure
2026-05-20 20:43 · Yahoo
Phibro Animal Health (PAHC): Buy, Sell, or Hold Post Q1 Earnings?
2026-05-19 14:04 · Yahoo
PAHC or SYK: Which Is the Better Value Stock Right Now?
2026-05-18 15:40 · Yahoo
1 Unpopular Stock That Should Get More Attention and 2 We Avoid
2026-05-14 01:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.